Business Context and Reporting Period
This Form 8-K filing by Prestige Brands Holdings, Inc. (referred to as Prestige Consumer Healthcare Inc. in metadata) is dated March 21, 2006. The report details a significant leadership transition and the execution of new senior management agreements effective April 1, 2006.
Key Financial Metrics and Compensation
The filing does not provide consolidated revenue, profit, cash flow, or debt metrics. It focuses exclusively on executive compensation terms:
- Peter C. Mann (Outgoing CEO): Annual base salary reduced from $442,000 (through March 31, 2006) to $225,000 (commencing April 1, 2006). Target bonus is 75% of base salary with a maximum of 150%. 140,686 shares vested immediately; an additional 140,686 shares vest if employed through March 1, 2007.
- Frank P. Palantoni (Incoming CEO): Annual base salary set at $400,000. Target bonus is 75% of base salary. A restricted stock grant valued at $525,000 is scheduled for July 1, 2006. Previous agreements include a $400,000 restricted stock grant and options to purchase $800,000 worth of stock at $12.95 per share.
Material Changes Versus Prior Period
The primary material change is the succession of the Chief Executive Officer role:
- Leadership Transition: Peter C. Mann will relinquish the CEO title on April 1, 2006, remaining as Chairman of the Board and Director. Frank P. Palantoni will assume the role of CEO and President, stepping down from his position as Chief Operating Officer.
- Contractual Updates: The new agreements supersede the Amended and Restated Senior Management Agreement dated February 4, 2005, which previously set Mr. Mann's salary at $425,000 per annum.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, revenue outlook, or specific risk factors regarding the company's operations. However, it notes the following contingencies and covenants:
- Restrictive Covenants: Mr. Mann is subject to non-compete restrictions until February 6, 2010, and must assign all work product and intellectual property to the company.
- Repurchase Rights: The company retains the right to repurchase Mr. Mann's unvested shares at the lesser of original cost or fair market value if his employment ceases.
- Performance Criteria: Bonus payments for both executives are contingent on subjective and objective criteria to be adopted by the Board and Compensation Committee.
Key Facts for Investor Verification
- Verify the exact vesting schedule and performance metrics for Frank P. Palantoni's $400,000 restricted stock grant mentioned in his prior August 2005 agreement.
- Confirm the impact of the leadership change on the company's strategic direction, as detailed in the press release (Exhibit 99.2) referenced in the filing.
- Monitor the July 1, 2006, issuance of restricted stock to Mr. Palantoni to assess dilution effects based on the share price at that time.
- Note that the filing text does not provide current financial performance data (revenue, earnings, or cash flow) for the period.